{"id":390766,"date":"2017-12-19T00:00:00","date_gmt":"2017-12-19T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/acreim0015-2017-biopharma-atopic-dermatitis-access-and-reimbursement-eu-2017\/"},"modified":"2026-04-22T05:25:35","modified_gmt":"2026-04-22T05:25:35","slug":"acreim0015-2017-biopharma-atopic-dermatitis-access-and-reimbursement-eu-2017","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/acreim0015-2017-biopharma-atopic-dermatitis-access-and-reimbursement-eu-2017\/","title":{"rendered":"Atopic Dermatitis | Access and Reimbursement | EU | 2017"},"content":{"rendered":"<p>Atopic dermatitis (AD) is a chronic, pruritic inflammatory skin disease that usually affects children but can persist or start in adulthood. For many years, the treatment landscape has remained stagnant, with topical agents dominating the treatment algorithm\u00a0and systemic immunosuppressants such as azathioprine and cyclosporin largely used in patients whose disease is inadequately controlled. Expected approval of Sanofi\/Regeneron\u2019s IL-4\/IL-13 inhibitor dupilumab in 2018 should give moderate to severe atopic dermatitis patients a promising targeted therapy option, with AstraZeneca\/Leo Pharma\u2019s tralokinumab and Roche\/Gladerma\u2019s lebrikizumab potentially strengthening the field in 2021. However, uptake of these premium-priced agents will strongly depend on EU5 payers\u2019 willingness to reimburse, and on country-specific prescribing controls.<\/p>\n<p><strong>Questions\u00a0Answered in \u00a0this Report:<\/strong><\/p>\n<ul>\n<li>\u00a0The topical agents are the mainstay of the AD market. The conventional systemics are mainly used in moderate to severe patients\u00a0who respond inadequately to topicals. <strong>What are the current prescribing practices for AD\u00a0in the EU5, and how, if at all, are these impacted by payer policy?\u00a0<\/strong><\/li>\n<li>Currently, no biologics are approved for AD; however, European AD guidelines do recommend off-label use of some biologics in severe patients if they are refractory to topicals and conventional systemics. <strong>To what extent are off-label conventional systemics such as methotrexate and off-label biologics like Novartis\/Roche\u2019s Xolair (omalizumab) used for moderate to severe AD? How do payers cover any such off-label prescribing?<\/strong><\/li>\n<li>Currently available AD therapies are inexpensive and therefore payers are generally not too concerned about the cost of overall AD treatment. However, this situation will change soon with the potential entry of the first biologic in 2018. <strong>What are payer and physician perspectives on promising but costly emerging agents such as dupilumab? What key market access challenges will manufacturers of novel AD therapies face? What can they do to encourage optimal pricing and reimbursement terms, and to drive uptake?<\/strong><\/li>\n<\/ul>\n<p><strong>Scope:<\/strong><\/p>\n<ul>\n<li><strong>Markets covered<\/strong>: France, Germany, Italy, Spain, and United Kingdom<\/li>\n<li><strong>Methodology<\/strong>: Surveys of 250 dermatologists and 10 country-specific interviews with European payers<\/li>\n<li><strong>Indication coverage<\/strong>: atopic dermatitis (AD)<\/li>\n<li><strong>Key drugs covered<\/strong>:\u00a0\u00a0prescription topical corticosteroids, topical calcineurin inhibitors, methotrexate, cyclosporin, azathioprine, mycophenolate mofetil, Toctino, dupilumab, tralokinumab, and lebrikizumab<\/li>\n<li><strong>Key companies mentioned<\/strong>:\u00a0 Sanofi, Regeneron,\u00a0 AstraZeneca, Leo Pharma,\u00a0 Roche, \u00a0and Novartis<\/li>\n<\/ul>\n","protected":false},"template":"","class_list":["post-390766","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-date-890"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390766","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390766\/revisions"}],"predecessor-version":[{"id":393890,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390766\/revisions\/393890"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390766"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}